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Background: The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use
in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy
(partial responders). This study aimed to explore the dose–response effect of lesogaberan on reflux episodes in
partial responders.
Methods: In this randomized, single-centre, double-blind, crossover, placebo-controlled study, partial responders
taking optimised PPI therapy were given 30, 90, 120 and 240 mg doses of lesogaberan. Each dose was given twice
(12 h apart) during a 24-h period, during which impedance–pH measurements were taken.
Results: Twenty-five patients were included in the efficacy analysis and 27 in the safety analysis. The effect of
lesogaberan on the mean number of reflux episodes was dose-dependent, and all doses significantly reduced the
mean number of reflux episodes relative to placebo. Lesogaberan also dose-dependently reduced the mean
number of acid reflux episodes (except the 30 mg dose) and weakly acid reflux episodes (all doses) significantly,
relative to placebo. Regardless of dose, lesogaberan had a similar effect on the percentage of time with esophageal
pH < 4 [mean reduction: 68.5% (30 mg), 54.2% (90 mg), 65.9% (120 mg), 72.1% (240 mg); p < 0.05 except 90 mg
dose]. No adverse events led to discontinuation and no serious adverse events occurred during active treatment.
Conclusions: Lesogaberan inhibited reflux in a dose-dependent manner in partial responders taking optimised PPI
therapy, and these effects were significant versus placebo. All lesogaberan doses were well tolerated and were not
associated with clinically relevant adverse events.
Trial registration: ClinicalTrials.gov identifier: NCT01043185.
Keywords: Gastroesophageal reflux, Lower esophageal sphincter, GABA-B agonist, Dose–response, Clinical studyBackground
Gastroesophageal reflux disease (GERD) is widespread,
affecting approximately 10–20% of people in Europe and
North America [1]. The primary symptoms of GERD –
heartburn and regurgitation – are thought to occur because
the lower esophagus is exposed to the acid contents of the
stomach, predominantly as a result of transient lower
esophageal sphincter relaxations (TLESRs) [2]. Current* Correspondence: Philip-Miner@ofdr.com
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unless otherwise stated.pharmacological treatments for GERD focus on the
suppression of gastric acid secretion by the use of proton
pump inhibitors (PPIs). Although PPI therapy is effective in
most patients with GERD, approximately 20–30% continue
to experience reflux symptoms despite PPI treatment [3].
TLESRs are thought to be responsible for about 80% of
reflux episodes in patients with GERD, and are therefore a
suitable target for treatment [4,5]. This strategy may be
particularly appropriate for patients who have reflux symp-
toms despite taking a PPI because such symptoms, when
not attributed to suboptimal PPI therapy and/or poor PPItd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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esophagus to weakly acid or non-acid reflux [3,6-8].
The stimulation of γ-aminobutyric acid type B receptors
(GABAB), both peripherally and centrally, has been shown
to inhibit TLESRs [9]. The GABAB agonist baclofen has
been used to inhibit TLESRs and reflux episodes, both in
healthy individuals and in patients with GERD, but the
central effects of tiredness and sleepiness have prevented
widespread use of this drug [10-13].
The novel GABAB agonist lesogaberan (AZD3355)
significantly inhibits TLESRs and reflux episodes in
humans, but has been assessed only as a single 0.8 mg/
kg dose and a twice-daily 65 mg dose [14,15]. The aim
of this study was to explore the dose–response effects
of lesogaberan, relative to placebo, on reflux variables,
and on the pharmacokinetics, and safety and tolerability




This study was carried out at a single centre in the USA
(Oklahoma Foundation for Digestive Research) and all
patients gave written, informed consent before entering
the study.
Participants were all patients with GERD who had a par-
tial response to PPI treatment. Criteria used to identify
this group of men and women were: a history of GERD
symptoms of at least 6 months in addition to ongoing
symptoms [defined as ≥ 3 days with at least moderate
heartburn (burning feeling behind the breastbone) or ≥
3 days with at least moderate regurgitation (unpleasant
movement of material upwards from the stomach)]
reported in the 7-day recall Reflux Symptom Question-
naire (RESQ-7) administered within 21 days of study
entry; continuous treatment in the 4 weeks before
enrolment with daily, optimized and unchanged PPI ther-
apy, with doses according to the US label for any GERD
indication (an optimized PPI treatment is a treatment that,
according to the investigator’s judgement, cannot be
improved further by changing brand or dose regimen);
and completion of 8 weeks of treatment with a PPI in
patients with reflux esophagitis verified by endoscopy in
the 8 weeks before enrolment. Participants were also
required to be healthy (other than having GERD) men or
women, aged 18–70 years, with a body mass index (BMI)
of 18.5–35.0 kg/m2, and with clinically normal physical
findings and laboratory values at the pre-entry visit. In
addition, participants had to have a PPI prescription with
refills covering the entire study period, or physician instruc-
tions to use equivalent over-the-counter PPI medication.
Patients were excluded if they had shown no improve-
ment in GERD symptoms during PPI therapy. Other
exclusion criteria were the concomitant use of drugs thathave a narrow therapeutic window (such as warfarin or
digoxin) or that could interfere with the pharmacody-
namic effects of lesogaberan (such as baclofen or supple-
ments containing GABA), alter gastrointestinal symptoms
(such as type 2 histamine receptor agonists) or damage
the mucosal lining of the gastrointestinal tract (such as
non-steroidal anti-inflammatory drugs, or acetylsalicylic
acid in doses > 162 mg/day). Individuals were also ex-
cluded if they had clinically significant disorders that
could interfere with the study or compromise patients’
safety (e.g. cardiovascular, respiratory, hepatic, renal, meta-
bolic, psychiatric or neurological disorders, or gastrointes-
tinal disorders besides GERD), or had a history of syncope,
heart disease, malignant disease, drug addiction or abuse,
electrolyte imbalances or severe allergic or hypersensitive
reactions. Pregnant or breastfeeding women were also
excluded from the study (women of childbearing age were
required to use effective contraceptive measures).
Study drugs, design and ethics
This was a randomized, double-blind, placebo-controlled,
four-way crossover, phase 2a study. An outline of the study
design is shown in Figure 1. Patients were randomized to
receive one of 10 treatment sequences each consisting of
placebo and three of the four different lesogaberan doses
(30, 90, 120 and 240 mg). These were given on different
days, each separated by a 7–28-day washout period. This
washout period far exceeds the likely maximum duration
of pharmacological activity, which is conventionally esti-
mated as five times the pharmacological half-life of a drug
(which, for lesogaberan, is approximately 11–13 h) [16],
meaning that at maximum only 0.01% of the peak concen-
tration (Cmax) remains at the end of the wash-out period.
Each dose was given twice over a 24-h period in the form
of modified-release capsules: one taken 1 h before break-
fast after fasting the night before, and the other taken 1 h
before dinner. (Note that patients fasted overnight before
each study period: no food after 22:00 and no fluids
after 24:00.) Treatment with patients’ usual, regular and
optimized dose of PPI was continued throughout the
study.
The study (ClinicalTrials.gov identifier: NCT01043185)
was designed and performed in accordance with ethical
principles originating in the Declaration of Helsinki,
and the study was consistent with guidelines of the
International Conference on Harmonisation and Good
Clinical Practice, regulatory requirements, and the
AstraZeneca policy on bioethics and human biological
samples. In addition, the University of Oklahoma Health
Sciences Centre’s Institutional Review Board approved the
study protocol. The investigator obtained signed informed
consent from the potential patients, assigned them unique
enrolment numbers, determined patient eligibility and
assigned eligible patients unique randomization codes.
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6



























7–28 days 7–28 days 7–28 days 5–10 days
Figure 1 Study design. Patients were assigned to four of five treatments by being randomized (R) to one of the following treatment sequences:
EABC (n = 2), ABCE (n = 3), BCED (n = 3), CEDB (n = 3), EDBA (n = 3), DABE (n = 3), ABEC (n = 2), BECD (n = 2), ECAD (n = 3) or CADE (n = 3), where
A, B, C and D correspond to lesogaberan 30, 90, 120 and 240 mg, respectively, and E corresponds to placebo. The randomization was performed
in blocks of consecutive patient numbers.
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secutive patients using a scheme generated by AstraZeneca
R&D, Mölndal, Sweden, using the global randomization
system (GRand). All investigators and study personnel
were blinded to patient randomization.
The primary objective of the study was to estimate the
dose–response effects of lesogaberan, in partial responders
taking optimised PPI therapy, on the total number of
reflux episodes during a 24-h period (primary variable).
Secondary objectives included assessing the effect over
24 hours of the 4 different doses of lesogaberan (AZD3355)
compared to placebo, on the number of reflux episodes
(total, acid, weakly acid and non-acid), the relationship
between reflux episodes and GERD symptoms, the height
(proximal extent) and content (liquid, gas) of reflux, and
the time with esophageal pH < 4 (esophageal acid exposure)
during the 24-h period. The pharmacokinetics [area under
the curve (AUC), Cmax and time to reach Cmax (tmax)] and
the safety and tolerability profiles of lesogaberan in relation
to dose were also assessed as part of the secondary objec-
tives of the study, as was the relationship between the
pharmacokinetics and pharmacodynamics of lesogaberan.Pharmacodynamic assessments
Impedance–pH measurements were taken for 24 h after
the first administration of each dose using a Sleuth®
multichannel intraluminal impedance ambulatory system
(Sandhill Scientific, Inc., Highlands Ranch, CO, USA).
This device includes a data logger, impedance–pH am-
plifiers, and a catheter consisting of two antimony pH
sensors (calibrated before and after recordings were
taken using standard pH 7 and pH 1 buffers) placed
5 cm above and 10 cm below the lower esophageal
sphincter (LES) and eight impedance electrodes placed
2, 4, 6, 8, 10, 14, 16 and 18 cm above the LES. The elec-
trodes are paired to measure impedance at 3, 5, 7, 9, 15
and 17 cm above the LES. The position of the LES waslocated by a manometric recording before the study
medication or placebo was given.
Impedance–pH readings were analysed by one investigator
(JP) using dedicated software (BioVIEW Analysis®, version
5.5.4; Sandhill Scientific Inc.) and were then checked manu-
ally. This was performed in a blinded manner and the results
were used to determine the number of reflux episodes,
defined as a period when impedance decreased to less than
50% of baseline (liquid episode) or increased to more than
150% of baseline (gas episode), propagating aborally from
the most distal channel. Acid, weakly acid and non-acid
reflux episodes were defined as episodes lasting longer than
5 s with a pH of < 4, 4.0–6.5 and > 6.5, respectively [17]. The
decision to use a cautious cut-off pH of 6.5 was taken in
order to ensure that no measurements near to a pH of 7
would be erroneously categorized as weakly acidic. These
definitions have previously been employed for studies of this
type [18]. During the 24-h period of ambulatory imped-
ance–pH measurement, patients used a data logger and a
diary card to record their meal intake and periods in supine
position, as well as any GERD symptoms.
Pharmacokinetic and safety assessments
Blood samples were taken 1 h before the first administra-
tion of each dose, and at regular intervals during the 24-h
period after the first administration of each dose, to assess
the concentration of lesogaberan in plasma over time.
Sitting and orthostatic blood pressure and pulse rate
were also assessed pre-dose and 2 h after the first dose of
lesogaberan or placebo at each treatment visit. Patients ate
meals (standardized primarily according to fat content
and pH) approximately 1 h after each dose of study medi-
cation or placebo, and at the same time points during each
study period. Patients were monitored for adverse events
from the first dose administration until the follow-up visit
5–10 days after receiving the last dose. The active treat-
ment period for each dose was defined as the time from
the first dose of study drug to 24 h after the second dose
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underwent active questioning to determine whether
they experienced syncope, or feeling faint, lightheaded-
ness, dizziness or paraesthesia before study treatment
started and after removing the impedance–pH catheter.
A 12-lead digital electrocardiogram (ECG) was sched-
uled at the screening visit, before and 2 h after the first
dose of lesogaberan or placebo at each treatment visit,
and at the follow-up visit. Blood and urine samples
were taken at the pre-entry visit (full laboratory screen),
and before and 24 h after the first dose of lesogaberan
or placebo at each treatment visit (reduced laboratory
screen) to assess clinical chemistry and haematology,
and to screen for indications of drug abuse.
Statistical analysis
The efficacy evaluation of the different doses of lesogaberan
was based on data from all patients not affected by major
protocol deviations and violations relevant to the analysis
of a specific variable. The safety analysis set comprised allFigure 2 Study flow. In total, 27 patients were randomised to receive plac
assigned treatment sequences shown in Figure 1 (26 patients completed t
evaluable dataset used to estimate the dose–response effects of lesogaberpatients who received at least one dose of lesogaberan or
placebo, and for whom post-dose data were available. The
pharmacokinetic analysis set was based on a subset of the
safety analysis set and only included patients with no major
protocol deviations thought to affect pharmacokinetics
significantly.
The sample size was based on data from a previous clin-
ical trial of lesogaberan, conducted by Boeckxstaens and col-
leagues [14], in which the geometric mean number of total
reflux episodes was 30.6 (95% confidence interval [CI] 20.9,
44.7). This corresponded to an approximately two-fold dif-
ference between the upper and lower CI limits, which was
sufficient to resolve statistically significant differences rela-
tive to placebo. The between and within-subject standard
deviation in the Boeckxstaens et al. study was 0.79 and 0.25,
respectively. This level of variability was incorporated
into a statistical model, based on the current study
design and a sample size of 20 patients. The resulting
simulation predicted 95% CI intervals for the geometric
mean number of total reflux episodes (the primaryebo and 3 of the 4 doses of lesogaberan, based on the randomly
he study). Overall, 7 poor-quality traces were excluded from the final
an (primary outcome).
Table 1 Pharmacodynamic effects of lesogaberan 30, 90, 120 and 240 mg relative to placebo (efficacy analysis set; n = 25)
Lesogaberan dose (mg) Difference in geometric mean (%) 95% CI p value*
Total number of reflux episodes†
30 −26.2 −12.7 to −37.6 0.0006
90 −37.0 −25.0 to −47.1 < 0.0001
120 −45.0 −35.5 to −53.1 < 0.0001
240 −52.8 −44.3 to −60.0 < 0.0001
Number of reflux episodes in upright position
30 −25.2 −11.1 to −37.1 0.0013
90 −38.4 −26.3 to −48.5 < 0.0001
120 −46.1 −36.5 to −54.2 < 0.0001
240 −50.7 −41.5 to −58.4 < 0.0001
Number of reflux episodes in supine position
30 −37.3 +2.0 to −61.5 0.0597
90 −12.3 +45.2 to −47.0 0.6042
120 −31.2 +9.3 to −56.7 0.1117
240 −69.1 −50.0 to −80.9 < 0.0001
Number of acid reflux episodes†
30 −34.7 +3.2 to −58.6 0.0677
90 −45.5 −12.3 to −66.1 0.0132
120 −57.9 −35.0 to −72.7 0.0002
240 −57.1 −32.5 to −72.7 0.0004
Number of weakly acid reflux episodes†
30 −28.3 −7.5 to −44.5 0.0113
90 −31.4 −10.7 to −47.4 0.0059
120 −44.5 −29.2 to −56.4 < 0.0001
240 −45.1 −29.3 to −57.3 < 0.0001
Number of pure liquid reflux episodes†
30 −27.9 +0.6 to −48.3 0.0540
90 −53.0 −33.6 to −66.7 < 0.0001
120 −44.1 −23.3 to −59.2 0.0005
240 −51.9 −33.1 to −65.4 < 0.0001
Number of mixed gas/liquid reflux episodes†
30 −25.0 −5.1 to −40.7 0.0175
90 −28.3 −8.4 to −43.8 0.0084
120 −42.5 −28.1 to −54.0 < 0.0001
240 −56.7 −45.4 to −65.7 < 0.0001
Proximal extent of reflux (cm)†
30 −39.1 −4.5 to −61.2 0.0312
90 −58.9 −34.4 to −74.2 0.0003
120 −66.3 −48.3 to −78.0 < 0.0001
240 −63.3 −42.8 to −76.5 < 0.0001
Proportion of time with esophageal pH < 4,%†
30 −69.8 −27.3 to −87.4 0.0083
90 −56.1 +9.0 to −82.3 0.0752
120 −65.7 −21.1 to −85.1 0.0126
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Table 1 Pharmacodynamic effects of lesogaberan 30, 90, 120 and 240 mg relative to placebo (efficacy analysis set; n = 25)
(Continued)
240 −73.0 −35.6 to −88.6 0.0037
Proportion of time with intragastric pH < 4,%†
30 +40.4 +10.3 to +78.8 0.0066
90 +23.7 −3.8 to +58.9 0.0957
120 +3.6 −17.7 to +30.3 0.7625
240 +27.7 +0.6 to +62.1 0.0451
CI, confidence interval.
*Based on a mixed-effect analysis of variance model for log-transformed data.
†In upright or supine position.
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tween the upper and lower limits. A sample size of 20
patients was therefore deemed sufficient for the current
study, based on at least 14 patients being assigned to
each of the lesogaberan 30 mg and 240 mg doses, 16 to
each of the lesogaberan 90 mg and 120 mg doses, and
20 to placebo. To ensure the minimum number of
patients had evaluable data for each dose, 27 patients
were randomized.
The effect of each dose of lesogaberan was measured as
the proportional difference, relative to placebo, in the
geometric mean of the reflux variables assessed over 24 h.
The analysis was based on a mixed-effect model with
treatment, period and sequence as fixed effects and
patient as a random effect. Geometric means and relative
differences in geometric means were reported with 95%
CIs. A p value of < 0.05 was considered to indicate statis-
tical significance and no corrections for multiple testing
were performed. Multiplicity was accounted for by using a
step-down sequential procedure comparing lesogaberan
doses with placebo, starting at a 240 mg dose and, in the
event of rejection of the null hypothesis, comparison of
descending doses [19].
The relationship between the pharmacokinetics and
pharmacodynamics of lesogaberan was investigated by
estimating the exposure–response curve and dose–
response curve. This was done using a mixed-effect Emax
model to explore the mean values of the number of
reflux episodes measured for 0–24 h against the dose of
lesogaberan used and the mean plasma concentration of
lesogaberan observed for each dose.
Results
Patient flow, follow-up and baseline characteristics
The first patient was enrolled on 17 December 2009 and
the last patient visit occurred on 7 May 2010. To assess
eligibility for the study, 45 patients were pre-screened by
telephone. Subsequently, 18 patients were excluded (four
were on exclusionary concomitant medications; one had
an exclusionary concurrent medical condition; one did
not meet the BMI criteria; five did not have enoughbreakthrough GERD symptoms; five were not on an ac-
ceptable PPI regimen; one had recently donated blood;
one could not meet the study visit schedule demands
Figure 2). In total, 27 participants were therefore ran-
domized to receive study medication, with a mean age of
43 years (range: 18–68 years) and a mean BMI of 30 kg/
m2 (range: 23–34 kg/m2). Of these, 52% (14/27 patients)
were male; 93% (25/27 patients) were white; and 11% (3/
27 patients) were current smokers. Current optimized PPI
therapy consisted of esomeprazole 20 mg (2 patients),
esomeprazole 40 mg (2 patients), lansoprazole 15 mg (2 pa-
tients), omeprazole 20 mg (18 patients), omeprazole 40 mg
(1 patient) and pantoprazole 40 mg (2 patients). One pa-
tient was subsequently lost to follow-up after testing posi-
tive for drug abuse. The pH–impedance data obtained
from some of the treatment arms for three patients were
excluded from the efficacy analysis because of poor quality
tracings (Figure 2). Within the efficacy analysis set, 24
patients received placebo, and the numbers in each lesoga-
beran dose group were: 30 mg, n = 18; 90 mg, n = 17;
120 mg, n = 20; 240 mg, n = 18. Overall, very few symptoms
were reported across the treatment groups (median of 0
symptoms during dosing with lesogaberan 120 mg, 0.5
symptoms for lesogaberan 240 mg, and 1.0 symptom for
lesogaberan 30 mg and 90 mg and for placebo. Meaningful
statistical analyses were therefore not possible for these
data.
Both the pharmacokinetic and safety analysis sets con-
sisted of all 27 randomized patients. Patients entering
this study had, on average, 163 months’ history of reflux
symptoms (range: 12–360 months). No patients had a his-
tory of hiatal hernia, one patient had a history of erosive
esophagitis, and seven (26%) tested positive for Helicobacter
pylori infection.
Efficacy (pharmacodynamic) results
Number of reflux episodes
During treatment with all four doses of lesogaberan, the
mean total number of reflux episodes was significantly
reduced relative to periods during which placebo was
given (Table 1; all p < 0.001). The magnitude of the effect
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dose-dependent (Figure 3A), with a reduction in the
mean number of reflux episodes of 26.2% relative to
placebo in patients receiving the 30 mg dose, compared
with a mean reduction of 52.8% in patients receiving the
240 mg dose. Most reflux episodes occurred while patients
were in an upright position and the dose-dependent
effects of lesogaberan were more apparent for this type of
reflux (Figure 3A). For patients in a supine position, the
only statistically significant reduction relative to placebo
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Figure 3 Observed effects (efficacy analysis set) of lesogaberan 30, 90
number of reflux episodes; (B) the number of acid and weakly acid re
liquid/gas reflux episodes. Data are presented as geometric means withthe highest dose of lesogaberan (69.1%; p < 0.0001;
Table 1). Data on reflux variables obtained from patients
while in a supine or upright position are combined from
this point onwards.
Lesogaberan reduced the mean number of acid and
weakly acid reflux episodes in a dose-dependent manner
(Figure 3B), with the only non-significant decrease
occurring for lesogaberan 30 mg in relation to acid
reflux (p = 0.068; Table 1). All four doses of lesogaberan
significantly reduced the mean number of mixed gas/liquid
reflux episodes relative to placebo (Table 1; all p < 0.05),Lesogaberan 90 mg (n = 17)
Lesogaberan 120 mg (n = 20)
Lesogaberan 240 mg (n = 18)
Placebo (n = 24)
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Figure 4 Observed effects (efficacy analysis set) of lesogaberan
30, 90, 120 and 240 mg compared with placebo on: (A) the
proximal extent of reflux; and (B) the proportion of time with
esophageal pH < 4. Data are presented as geometric means with
95% confidence intervals.
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of lesogaberan (Figure 3C). A dose-dependent effect for
lesogaberan was less clear for pure liquid reflux (Figure 3C),
with similar reductions of 53.0%, 44.1% and 51.9% observed
for lesogaberan 90, 120 and 240 mg, respectively (Table 1).
However, the smallest reduction in the mean number of
pure liquid reflux episodes relative to placebo was observed
for lesogaberan 30 mg, and this was the only dose that did
not significantly reduce this type of reflux (p = 0.0540;
Table 1). No significant effect was detected for lesogaberan
relative to placebo in terms of the mean number of pure
gas reflux episodes or the mean number of non-acid reflux
episodes (data not shown).
Other reflux characteristics
Relative to placebo, all four doses of lesogaberan signifi-
cantly reduced the mean number of reflux episodes that
had a proximal extent at least 15 cm above the LES
(Table 1; all p < 0.05). Lesogaberan 90, 120 and 240 mg
reduced the proximal extent of reflux to a similar extent
relative to placebo (Table 1 and Figure 4A). Three of the
four doses (30, 120 and 240 mg) of lesogaberan signifi-
cantly reduced esophageal acid exposure relative to pla-
cebo (all p < 0.05), but this did not appear to occur in a
dose-dependent manner (Table 1 and Figure 4B). Intra-
gastric acid exposure was significantly increased relative
to placebo in patients receiving lesogaberan 30 mg and
240 mg (Table 1; both p < 0.05).
Pharmacokinetic results
For all four doses of lesogaberan, absorption from the
bloodstream was rapid (Table 2; geometric mean tmax
1.7–2.6 h) and plasma concentrations decreased at a
similar rate for each dose in the 12-h periods that
followed each administration (Figure 5). Exposure to
lesogaberan, as assessed by AUC and Cmax values, varied
in proportion to the doses of lesogaberan that were
administered (Table 2). A relationship was observed
between the number of reflux episodes and the level of
exposure to lesogaberan (Figure 6A) and the dose of
lesogaberan (Figure 6B).
Safety and tolerability assessments
During active dosing, one patient reported headache and
nausea while taking lesogaberan 90 mg and one had viral
gastroenteritis while taking placebo. No serious adverse
events were reported during active dosing periods and
no adverse events resulted in discontinuation. One serious
adverse event (reversible elevated blood creatinine, alanine
aminotransferase and aspartate aminotransferase levels fol-
lowing recent heavy exercise) was detected at the follow-
up visit (i.e. not during active dosing) in one patient, but
this was not deemed by the investigator to be related to
study drug. Slight increases in pulse rate and slightdecreases in blood pressure were observed in patients
taking lesogaberan compared with those taking placebo,
in line with results from previous studies. Orthostatic
reactions occurred in three patients, but none had any
clinical symptoms and no cardiovascular adverse events
occurred. No clinically significant changes in ECG read-
ings were observed.Discussion
The primary objective of this study in patients with a par-
tial response to PPI treatment who were taking optimised
PPI therapy was to assess the effects of different doses of
lesogaberan (given twice daily on a single day), relative to
Table 2 Pharmacokinetic measures in patients during dosing with lesogaberan 30 (n = 18), 90 (n = 20), 120 (n = 21) and
240 mg (n = 19)
Parameter Lesogaberan dose (mg) Geometric mean Coefficient of variation (%)




















AUC, area under the curve; Cmax, peak concentration; tmax, time to reach peak concentration.
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24-h period.
The dose range of lesogaberan that was used in this
study was comprehensive in that it encompassed doses
both higher and lower than the 65 mg dose used in previ-
ous studies in patients with GERD and in patients with
GERD who had persistent reflux symptoms despite PPI
treatment [14,20], as well as including a maximum thera-
peutic dose of 240 mg. The double-blind, crossover design
chosen for this study minimized bias and variability, and
therefore the sample size needed was reduced. The use of
treatment and placebo groups, with patients maintaining
their PPI medication throughout the study, allowed the
dose-dependent effects of lesogaberan over and above
those of PPI therapy alone to be determined. Potential
limitations of crossover studies include the possibility of
carryover and sequence effects. While such effects can
never be completely excluded, they were minimised by the
large washout period used between treatments and by
randomisation of the treatment sequences. Another limi-
tation was the number of poor-quality traces obtained, al-
though the sample size used was sufficient to ensure that
the minimum evaluable data required to achieve adequate
statistical power were obtained. Issues of multiplicity,
which are a potential limitation when a high number of
treatment comparisons are made, were addressed using astep-down sequential procedure comparing lesogaberan
doses with placebo, starting at a 240 mg dose and, in the
event of rejection of the null hypothesis, comparison of
descending doses Finally, statistically significant reductions
in reflux episodes do not necessarily equate to clinically
relevant reductions in patients’ symptoms, as discussed in
further detail below.
Lesogaberan 65 mg (twice daily) has previously been
shown to reduce the mean number of total reflux episodes
by approximately 35% relative to placebo in patients with
GERD who have a partial response to PPI therapy [14].
This finding is consistent with the results of the current
study, with lesogaberan 30 mg and 90 mg reducing the
mean number of total reflux episodes by approximately
26% and approximately 37%, respectively. The greatest
reduction in the mean number of total reflux episodes of
approximately 53% was observed in patients receiving
lesogaberan 240 mg; dose–response curves indicate that
this is close to the maximum effect achievable for this
drug (Figure 6B). A similar maximum effect in terms of
TLESR reduction was observed in dogs in preclinical stud-
ies using lesogaberan at concentrations at which it has a
strictly peripheral mode of action [21]. These results indi-
cate that preclinical animal models can be used success-
fully to predict the clinical effects of novel therapeutics































































Figure 6 Number of reflux episodes over a period of 24 h.
Estimation using a mixed-effect Emax model of (A), the predicted
exposure–response curve with 95% CI curves (intersection of efficacy
and pharmacokinetics analysis set) and (B), the dose–response curve
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Lesogaberan 30 mg b.i.d. 
Lesogaberan 90 mg b.i.d. 
Lesogaberan 120 mg b.i.d. 
Lesogaberan 240 mg b.i.d. 
Figure 5 Arithmetic mean plasma concentration of
lesogaberan. Lesogaberan was administered as doses of 30, 90, 120
or 240 mg twice daily (b.i.d.) over a period of 24 h (pharmacokinetics
analysis set).
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http://www.biomedcentral.com/1471-230X/14/188Lesogaberan 65 mg (twice daily) given as an add-on
therapy to PPIs in patients with a partial response to PPI
treatment has also been shown in a phase 2a study to
significantly increase the proportion of patients whose
reflux symptoms respond to treatment (response defined
as a maximum of one 24-h period with heartburn and/
or regurgitation of not more than mild intensity during
the last 7 treatment days), although the proportion of
responders was small (8% for placebo vs. 16% for lesoga-
beran) [20]. The results of the current study suggest that
this effect could be improved using a higher dose of
lesogaberan. Nevertheless, a subsequent phase 2b study
has found that lesogaberan 240 mg does not have a clin-
ically important effect on GERD symptoms in partial
responders to PPI treatment [22] which, in combination
with some potential safety signals (reversible elevated
alanine transaminase levels >5 times the upper limit of
normal in 6 patients), led to the discontinuation of the
development of lesogaberan in 2012. One reason why
the effects of lesogaberan on TLESRs and acid exposure
did not translate into significant symptom relief could
be the presence of patients with functional heartburn in
the study population, which is likely given that symptom
criteria were used for the selection of patients, rather
than objective measures of GERD such as pH-metry.
These data show strong pharmacophysiological evidence
for targeting of the lower esophageal sphincter to reducereflux events. The fact that this reduction in reflux events
does not correlate with a reduction in symptom reporting
in the current study does not devalue the physiological
appropriateness of this mechanism; instead, it highlights
that our understanding of the relationship between reflux
events and patient-reported symptoms is still lacking [23].
An unexpected finding of the current study was that
lesogaberan significantly increased the percentage of
time with an intragastric pH < 4, despite decreasing the
number of acid reflux episodes and the percentage of
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http://www.biomedcentral.com/1471-230X/14/188time with an esophageal pH < 4. It is unclear why this
occurred in the current study, especially given that the
effect was highly variable, with significant increases in
gastric acidity only occurring at the lowest and highest
doses of lesogaberan. It is, however, worth noting that
the number of acid reflux episodes and percentage of
time with an esophageal pH < 4 could still be reduced
under these conditions, as long as reflux frequency
(i.e. the frequency at which stomach contents actually
reach the esophagus) and/or volume is reduced enough
to counteract any increase in gastric acidity. It must be
noted that the placebo group reported few symptoms
(median of 1.0 symptom) during the 24-h study period.
These patients may have adhered better to their treatment
during the study. However, the paucity of symptom data
did not allow us either to compare symptoms between
groups, or to relate symptoms to reflux inhibition.
Conclusions
In general, the results of this study were very clear, with
lesogaberan reducing most measures of reflux in a dose-
dependent manner, and the majority of these effects being
significant relative to placebo in partial responders taking
optimised PPI therapy. The dose-dependent effects of leso-
gaberan were consistent with the patients’ level of exposure
to this drug, with pharmacokinetic measures such as the
maximum AUC for plasma concentration and Cmax vary-
ing in proportion to the dose of lesogaberan. Moreover, all
doses of lesogaberan appeared to be associated with a good
tolerability profile and did not cause any serious or clinic-
ally relevant adverse events. In conclusion, this study
confirms that lesogaberan works as a reflux inhibitor in a
predictable, dose-dependent way.
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